| ln Vitro |
NC762 (0.01-100 nM) binds to B7-H4, with an EC50 of 1.12 nM in 624Mel.B7H4 cells and 0.976 nM in SKBR3 cells [2]. NC762 (0.1 ng/mL-100 μg/mL) binds to B7-H4 in human 293T cells but not to mouse B7-H4 [2]. NC762 (0.1 pM-1000 nM) binds to CD16a more readily than V5.hlgG1 [2]. NC762 (0.1-100 pM, 5 h) exhibits ADCC activity in 624Mel.B7H4 and SKBR3 cells co-cultured with effector Jurkat reporter cell lines [2].
|
|---|---|
| ln Vivo |
NC762 (1–30 mg/kg, intraperitoneal injection, once every 7 days for a total of 4 times) dose-dependently reduced tumor volume in NSG mice subcutaneously inoculated with 1E06 624Mel.hB7H4 cells and 3E05 human peripheral blood mononuclear cells (PBMCs) [2]. NC762 (10 mg/kg, intraperitoneal injection, once every 4 days for a total of 7 times) inhibited anti-B7H4-mediated, NK cell-involved tumor growth and prolonged the survival of NSG mouse models subcutaneously inoculated with a mixture of 1E06 624Mel.hB7H4 cells and 1E06 total PBMCs or NK cell-depleted PBMCs [2]. NC762 (10 mg/kg, intraperitoneal injection, once every 7 days for a total of 4 times) inhibited tumor growth in NSG mouse models subcutaneously inoculated with 1E06 624Mel.hB7H4 cells, regardless of the presence of PBMCs [2]. The tumor growth inhibition activity of NC762 (10 mg/kg, intraperitoneal injection, once every 7 days for a total of 4 times) is similar to that of the low Fc affinity mutant of NC762, suggesting that its tumor growth inhibition mechanism may not depend on ADCC[2].
|
| References |
|
| Appearance |
Colorless to light yellow liquid
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
